TB Diagnosis Based on Promiscuous PE-PGRS Epitopes

基于混杂 PE-PGRS 表位的结核病诊断

基本信息

  • 批准号:
    7660039
  • 负责人:
  • 金额:
    $ 25.38万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-04-01 至 2011-03-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): A simple sensitive and specific point-of-care test that can diagnose TB in both HIV- and HIV+ subjects is urgently needed for combating the raging TB epidemic. A subfamily of genes, called PE-PGRS genes is present in M. tuberculosis (complex), but there are no PE-PGRS genes in several other common mycobacterial pathogens including M. avium (which afflicts 5-7% of the HIV+ subjects) and M. leprae. This makes the PE-PGRS proteins attractive targets for inclusion into diagnostic tests for TB. Our preliminary studies demonstrate that immunodominant epitopes that are shared by several PE-PGRS proteins (promiscuous epitopes) are highly immunogenic in TB patients. Based on these results we propose to identify the PE-PGRS genes that are highly expressed in the lungs of tuberculous rabbits infected with aerosols of clinical isolates of M. tuberculosis, and map their immunodominant promiscuous epitopes recognized specifically by antibodies from HIV-TB+ and HIV+TB+ patients. These epitopes can be the basis of a simple peptide-based diagnostic test for TB. Specifically, we propose to: a) Identify the subset of PE-PGRS genes that is highly expressed by M. tuberculosis during growth and replication in lungs, and characterize the proteins (Aim #1); b) Dissect the PEPGRS proteins selected in Aim # 1 to delineate the immunodominant epitopes that are recognized by serum antibodies from HIV-TB+ and HIV+TB+ patients but not by PPD-, PPD+ and/or BCG vaccinated healthy subjects or HIV+TB- controls (Aim #2) and c) Evaluate the reactivity of epitopes identified in Aim #2 with sera from individual patients at different stages of TB to identify the optimal set of peptides and evaluate the optimal peptide-subset for reactivity with sera from patients from different geographical settings (Aim # 3). PUBLIC HEALTH RELEVANCE: The work proposed could lead to development of a cheap, reliable and rapid diagnostic test for TB. No reliable rapid tests for TB exist so far and this would be a major advancement in the field.
描述(由申请人提供):迫切需要一种简单、敏感和特异的即时检测方法,可以诊断HIV-和HIV+受试者的结核病,以抗击肆虐的结核病流行。在M.结核分枝杆菌(复合型)中存在PE-PGRS基因,但包括M. avium(其折磨5 - 7%的HIV+受试者)和M.麻风病人这使得PE-PGRS蛋白成为纳入TB诊断测试的有吸引力的靶标。我们的初步研究表明,由几种PE-PGRS蛋白共享的免疫显性表位(混杂表位)在TB患者中具有高度免疫原性。基于这些结果,我们提出鉴定肺结核兔肺中高表达的PE-PGRS基因,这些肺结核兔被临床分离的肺炎支原体气溶胶感染。结核病,并绘制其免疫显性混杂表位特异性识别的抗体从HIV-TB+和HIV + TB+患者。这些表位可以作为结核病简单肽基诊断试验的基础。具体而言,我们提出:a)鉴定由M高度表达的PE-PGRS基因子集。结核病在肺中的生长和复制过程中,并表征蛋白质(目标#1); B)解剖在目的#1中选择的PEPGRS蛋白以描绘被来自HIV-TB+和HIV + TB+患者的血清抗体识别但不被PPD-识别的免疫显性表位,PPD+和/或BCG接种的健康受试者或HIV + TB-对照(目标#2)和c)评估目标#2与来自TB的不同阶段的个体患者的血清进行比较,以鉴定肽的最佳集合,并评估与来自不同地理环境的患者的血清的反应性的最佳肽子集(目标#3)。公共卫生相关性:拟议的工作可能会导致开发一种廉价,可靠和快速的结核病诊断测试。到目前为止,还没有可靠的结核病快速检测方法,这将是该领域的一个重大进步。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Suman Laal其他文献

Suman Laal的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Suman Laal', 18)}}的其他基金

Research Training on Pathogenesis and Diagnosis of HIV-TB
HIV-TB发病机制和诊断研究培训
  • 批准号:
    8710874
  • 财政年份:
    2014
  • 资助金额:
    $ 25.38万
  • 项目类别:
Research Training on Pathogenesis and Diagnosis of HIV-TB
HIV-TB发病机制和诊断研究培训
  • 批准号:
    9049560
  • 财政年份:
    2014
  • 资助金额:
    $ 25.38万
  • 项目类别:
Research Training on Pathogenesis and Diagnosis of HIV-TB
HIV-TB发病机制和诊断研究培训
  • 批准号:
    9251930
  • 财政年份:
    2014
  • 资助金额:
    $ 25.38万
  • 项目类别:
Research Training on Pathogenesis and Diagnosis of HIV-TB
HIV-TB发病机制和诊断研究培训
  • 批准号:
    8853360
  • 财政年份:
    2014
  • 资助金额:
    $ 25.38万
  • 项目类别:
Rapid Diagnosis of Early TB in HIV+ Patients
HIV 患者早期结核病的快速诊断
  • 批准号:
    8678144
  • 财政年份:
    2013
  • 资助金额:
    $ 25.38万
  • 项目类别:
Rapid Diagnosis of Early TB in HIV+ Patients
HIV 患者早期结核病的快速诊断
  • 批准号:
    8338845
  • 财政年份:
    2011
  • 资助金额:
    $ 25.38万
  • 项目类别:
Rapid Diagnosis of Early TB in HIV+ Patients
HIV 患者早期结核病的快速诊断
  • 批准号:
    8121268
  • 财政年份:
    2011
  • 资助金额:
    $ 25.38万
  • 项目类别:
TB Diagnosis Based on Promiscuous PE-PGRS Epitopes
基于混杂 PE-PGRS 表位的结核病诊断
  • 批准号:
    7798073
  • 财政年份:
    2009
  • 资助金额:
    $ 25.38万
  • 项目类别:
Antibody Based Diagnosis for TB
基于抗体的结核病诊断
  • 批准号:
    7185856
  • 财政年份:
    2003
  • 资助金额:
    $ 25.38万
  • 项目类别:
Antibody Based Diagnosis for TB
基于抗体的结核病诊断
  • 批准号:
    7012835
  • 财政年份:
    2003
  • 资助金额:
    $ 25.38万
  • 项目类别:

相似海外基金

AEROSOLS
气雾剂
  • 批准号:
    10101317
  • 财政年份:
    2024
  • 资助金额:
    $ 25.38万
  • 项目类别:
    EU-Funded
AEROSOLS - AIR QUALITY AND HEALTH IMPACT OF PRIMARY SEMI-VOLATILE AND SECONDARY PARTICLES AND THEIR ABATEMENT
气溶胶 - 一次半挥发性颗粒和二次颗粒对空气质量和健康的影响及其消除
  • 批准号:
    10092043
  • 财政年份:
    2024
  • 资助金额:
    $ 25.38万
  • 项目类别:
    EU-Funded
Molecular-level Understanding Of Atmospheric Aerosols (MUOAA 2024); Corsica, France; April 1-5, 2024
对大气气溶胶的分子水平理解(MUOAA 2024);
  • 批准号:
    2332007
  • 财政年份:
    2024
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Standard Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
  • 批准号:
    NE/Y000021/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Research Grant
TWISTA (The Wide-ranging Impacts of STratospheric smoke Aerosols)
TWISTA(平流层烟雾气溶胶的广泛影响)
  • 批准号:
    NE/Y000358/1
  • 财政年份:
    2024
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Research Grant
Southern Ocean aerosols: sources, sinks and impact on cloud properties
南大洋气溶胶:来源、汇以及对云特性的影响
  • 批准号:
    DP240100389
  • 财政年份:
    2024
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Discovery Projects
An AI-driven clinical washbasin unit that automatically disinfects pathogens, reduces aerosols and decreases healthcare-acquired infections by 70%
%20人工智能驱动%20临床%20洗脸盆%20单位%20%20自动%20消毒%20病原体,%20减少%20气溶胶%20和%20减少%20医疗保健获得性%20感染%20by%2070%
  • 批准号:
    83001507
  • 财政年份:
    2023
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Innovation Loans
Cloudbusting with JWST: characterising aerosols, aurorae and chemistry in substellar atmospheresto the water cloud regime
使用 JWST 进行云消除:描述水云状态下恒星大气中的气溶胶、极光和化学成分
  • 批准号:
    ST/X001091/1
  • 财政年份:
    2023
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Research Grant
INvestigating Home water and Aerosols' Links to opportunistic pathogen Exposure (INHALE): do consumer decisions impact pathogen exposure and virulence?
调查家庭用水和气溶胶与机会性病原体暴露(吸入)的联系:消费者的决定是否会影响病原体暴露和毒力?
  • 批准号:
    2326096
  • 财政年份:
    2023
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Standard Grant
Bioactivated Aerosols for Combustion Product Capture
用于燃烧产物捕获的生物活性气溶胶
  • 批准号:
    10080253
  • 财政年份:
    2023
  • 资助金额:
    $ 25.38万
  • 项目类别:
    Small Business Research Initiative
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了